Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma

[1]  E. Giovannucci,et al.  A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. , 2014, Journal of the National Cancer Institute.

[2]  Li-ping Guo,et al.  Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy , 2014, Cancer science.

[3]  Robert Grützmann,et al.  Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. , 2013, International journal of surgery.

[4]  Lynette M. Smith,et al.  Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer , 2013, PloS one.

[5]  P. Albert,et al.  Serum Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15): A Potential Screening Tool for the Prevention of Colon Cancer? , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[6]  J. Hamilton,et al.  The TGF-β superfamily cytokine, MIC-1/GDF15: A pleotrophic cytokine with roles in inflammation, cancer and metabolism , 2011, Growth factors.

[7]  S. Köklü,et al.  Diagnostic Validity of Serum Macrophage Inhibitor Cytokine and Tissue Polypeptide-Specific Antigen in Pancreatobiliary Diseases , 2011, Pancreatology.

[8]  William E Grizzle,et al.  Serum Biomarker Panels for the Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.

[9]  H. Grönberg,et al.  Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15): a new marker of all‐cause mortality , 2010, Aging cell.

[10]  M. Mimeault,et al.  Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine‐1 in cancer , 2010, Journal of cellular physiology.

[11]  B. Davidson,et al.  Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. , 2010, Gynecologic oncology.

[12]  S. Huh,et al.  Macrophage inhibitory cytokine-1 regulates melanoma vascular development. , 2010, The American journal of pathology.

[13]  S. Batra,et al.  Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK–RhoA signaling pathway , 2010, Oncogene.

[14]  S. Paterson-Brown,et al.  Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer , 2010, British Journal of Cancer.

[15]  S. Park,et al.  Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. , 2009, Biochemical pharmacology.

[16]  S. Safe,et al.  Induction of apoptosis and nonsteroidal anti‐inflammatory drug‐activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative , 2009, Molecular carcinogenesis.

[17]  P. Parsons,et al.  Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. , 2009, The Journal of investigative dermatology.

[18]  Jung Joon Lee,et al.  Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. , 2008, Carcinogenesis.

[19]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  A. Jukkola-Vuorinen,et al.  Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases , 2007, Cancer Epidemiology Biomarkers & Prevention.

[21]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Goodwin,et al.  Pancreatic cancer in the general population: Improvements in survival over the last decade , 2006, Journal of Gastrointestinal Surgery.

[23]  C. Sternberg,et al.  Current therapies and advances in the treatment of pancreatic cancer. , 2006, Critical reviews in oncology/hematology.

[24]  H. Johnen,et al.  Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. , 2006, Cancer research.

[25]  D. Chan,et al.  Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 , 2006, Clinical Cancer Research.

[26]  G. Hampton,et al.  Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis , 2006, Clinical Cancer Research.

[27]  Y. Tian,et al.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  S. Saglam,et al.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma , 2004 .

[29]  K. Kinzler,et al.  Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers , 2004, Clinical Cancer Research.

[30]  J. Zaunders,et al.  Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. , 2003, Cancer research.

[31]  K. Song,et al.  Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. , 2003, Cancer research.

[32]  K. Kinzler,et al.  MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Welsh,et al.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Arrowsmith,et al.  Placental Transforming Growth Factor-β Is a Downstream Mediator of the Growth Arrest and Apoptotic Response of Tumor Cells to DNA Damage and p53 Overexpression* , 2000, The Journal of Biological Chemistry.

[35]  L. Koniaris,et al.  Characterization of Growth-Differentiation Factor 15, a Transforming Growth Factor β Superfamily Member Induced following Liver Injury , 2000, Molecular and Cellular Biology.

[36]  S. Vukicevic,et al.  Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.

[37]  W. D. Fairlie,et al.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Klimstra,et al.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. , 1996, Annals of surgery.

[39]  M. Plebani,et al.  Is CA242 really a new tumour marker for pancreatic adenocarcinoma? , 1995, Oncology.

[40]  上田晃久,et al.  Macrophage inhibitory cytokine‐1(MIC‐1)と糖尿病性腎症の関連について , 2016 .

[41]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[42]  S. Saglam,et al.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Kinzler,et al.  Secreted and cell surface genes expressed in benign and malignant colorectal tumors. , 2001, Cancer research.

[44]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[45]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.